mannitol has been researched along with vx-770 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ong, T; Ramsey, BW | 1 |
| Cavallaro, G; Di Leonardo, A; Giammona, G; Lentini, L; Porsio, B; Quaglia, F; Ungaro, F | 1 |
1 review(s) available for mannitol and vx-770
| Article | Year |
|---|---|
Modifying disease in cystic fibrosis: current and future therapies on the horizon.
Topics: Aminophenols; Biomarkers; Cell Membrane; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Genetic Markers; Genetic Therapy; Humans; Male; Mannitol; Mutation; Phenotype; Quinolones; Respiratory System Agents; Saline Solution, Hypertonic | 2013 |
1 other study(ies) available for mannitol and vx-770
| Article | Year |
|---|---|
Inhalable nano into micro dry powders for ivacaftor delivery: The role of mannitol and cysteamine as mucus-active agents.
Topics: Administration, Inhalation; Aminophenols; Animals; Cells, Cultured; Chloride Channel Agonists; Cysteamine; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Drug Compounding; Drug Liberation; Expectorants; Mannitol; Mutation; Nanoparticles; Peptides; Powders; Quinolones; Rats, Inbred F344 | 2020 |